Brilique 90mg Tablets
What this means
The MHRA has issued a medicines recall or defect notification. Class 1: risk to life, immediate recall. Class 2: may cause mistreatment or harm, recall within 48 hours. Class 3: unlikely to cause harm, recall within 5 days. Class 4 (defect notification): no recall, caution in use. The medicine remains licensed; only the listed batches are affected. Do not stop treatment without speaking to your doctor or pharmacist.
Class 4 defect notification · DMRC-34718431
| Product | Licence | Active ingredient | GTIN |
|---|---|---|---|
| Brilique 90mg Tablets | ticagrelor | 05059053010042 |
Background: G Pharma Ltd have informed the MHRA that there is an error in the spelling of the active ingredient included on the imported carton. The spelling should be ‘Ticagrelor’ but has been printed as ‘Tricagelor’ under the brand name and in the content statement. Advice for Healthcare Professionals Healthcare professionals are to be aware of the incorrect spelling of the active ingredient on the carton when prescribing and or dispensing the product.